Consensus ADC Therapeutics SA

Stocks

ADCT

CH0499880968

Biotechnology & Medical Research

Market Closed - NYSE Other stock markets 16:00:02 2026-07-02 EDT			5-day change	1st Jan Change
1.190 ^USD	+4.39%		+16.67%	-66.29%

06-30	ADC Therapeutics SA Completes Enrollment In LOTIS-7 Phase 1b ZYNLONTA Combination Trial	CI
06-30	ADC Therapeutics Completes Enrollment in LOTIS-7 Lymphoma Study	MT

Evolution of the Average Target: ADC Therapeutics SA

Evolution of the Target Price: ADC Therapeutics SA

Changes in Analyst Recommendations: ADC Therapeutics SA

ed0a30bb019d538ae.sK0ZVIyZfHVIDvk3uQNHS5Qy-D9jajkUyryEhYaSW7s.g-xqI7jMHRIES8lm30YuP-1kvF4xPU1wmvji1fK_D-vS3ksT5PpNIg5BtA~0b092b4f182ffba246d3ece6cfe1bfae

Analysts' recommendations: ADC Therapeutics SA

06-08	ADC Therapeutics Shares Fall After HC Wainwright Downgrade	MT
06-08	HC Wainwright Downgrades ADC Therapeutics to Neutral From Buy	MT
06-04	Top Midday Decliners	MT
06-04	RBC Downgrades ADC Therapeutics to Sector Perform From Outperform, Cuts Price Target to $2 From $6, Keeps Speculative Risk	MT
25-06-20	RBC Adjusts Price Target on ADC Therapeutics Ltd to $5 From $8, Maintains Outperform, Speculative Risk Rating	MT
24-11-08	Stephens Starts ADC Therapeutics With Overweight Rating, $6 Price Target	MT
24-05-30	Cantor Fitzgerald Initiates ADC Therapeutics at Overweight Rating	MT
24-05-07	HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating	MT
24-03-28	Guggenheim Initiates ADC Therapeutics With Buy Rating, $11 Price Target	MT
24-02-26	RBC Lifts Price Target on ADC Therapeutics to $8 From $6, 'Encouraged' by Competitive Positioning; Outperform, Speculative Risk Kept	MT
24-02-20	HC Wainwright Raises Price Target on ADC Therapeutics to $9 From $3, Maintains Buy Rating	MT
23-11-20	HC Wainwright Adjusts Price Target on ADC Therapeutics to $3 From $12, Keeps Buy Rating	MT
23-11-09	TD Cowen Downgrades ADC Therapeutics to Market Perform From Outperform	MT
23-11-08	RBC Cuts Price Target on ADC Therapeutics to $6 From $7, Keeps Outperform, Speculative Risk	MT
23-09-12	RBC Trims Price Target on ADC Therapeutics to $8 From $9 Amid Guidance Withdrawal, Keeps Outperform, Speculative Risk	MT
23-08-10	JPMorgan Upgrades ADC Therapeutics to Neutral From Underweight	MT
23-08-09	RBC Trims Price Target on ADC Therapeutics to $9 From $10, Maintains Outperform Rating, Speculative Risk Qualifier	MT
23-06-20	HC Wainwright Lowers Price Target on ADC Therapeutics to $12 From $20, Maintains Buy Rating	MT
23-05-10	RBC Cuts Price Target on ADC Therapeutics to $10 From $12, Maintains Outperform Rating, Speculative Risk Qualifier	MT
23-04-24	BofA Securities Downgrades ADC Therapeutics to Underperform From Neutral, Adjusts Price Target to $2 From $7	MT
23-02-13	RBC Cuts Price Target on ADC Therapeutics to $12 From $18, Maintains Outperform, Speculative Risk	MT
23-01-24	Morgan Stanley Lowers Price Target on ADC Therapeutics to $5 From $7, Maintains Equalweight Rating	MT
23-01-04	HC Wainwright Adjusts Price Target on ADC Therapeutics SA to $20 From $21, Maintains Buy Rating	MT
22-11-14	Morgan Stanley Adjusts Price Target on ADC Therapeutics SA to $7 From $11, Maintains Equal-Weight Rating	MT
22-11-09	BofA Securities Downgrades ADC Therapeutics to Neutral From Buy, Adjusts Price Target to $7 From $14	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ADC THERAPEUTICS SA					+320.17%
	ARGENX SE					+6.55%
	WUXI APPTEC CO., LTD.					+18%
	BIONTECH SE					+26.98%
	INSMED INCORPORATED					+76.57%
	WUXI BIOLOGICS (CAYMAN) INC.					+24.46%
	GENMAB A/S					+23.8%
	PHARMAESSENTIA CORPORATION					-26.02%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+9.75%
	EXELIXIS, INC.					-10.36%
	Average					+46.99%
	Weighted average by Cap.					+18.01%